An observational study in Osteoporosis, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in Korea, Republic of. Open to female participants. Per ClinicalTrials.gov, last updated 2021-03-09.
Sponsored by Hanmi Pharmaceutical Company Limited · Observational
This study examines quality of life and patient satisfaction in postmenopausal women receiving raloxifene to prevent/treat osteoporosis, and vitamin D to reduce risk of fracture using clinical practice data. The purpose of this study is to observe quality of life(QOL), medication compliance and patient satisfaction who got combination therapy with raloxifene/cholecalciferol (raloxifene 60mg + cholecalciferol 800 IU, Rabone D®, Hanmi Pharma, South Korea) for 6 months.
Preventing bone loss is an important concern for women during post-menopausal period. Menopause significantly speeds bone loss and increases the risk for osteoporosis. This study was to investigate the effectiveness on quality of life (QOL), patient satisfaction in postmenopausal women receiving raloxifene/cholecalciferol combination therapy. In addition, we analyzed adverse events to assess the safety profile of this drug.
This study is a multicenter, prospective, non-critical observational study of women receiving raloxifene/cholecalciferol (raloxifene 60mg + cholecalciferol 800 IU, Rabone D®, Hanmi Pharma, South Korea) combination therapy to treat or prevent postmenopausal osteoporosis. Data will be collected from patients receiving routine treatment at about 105 primary, secondary, or tertiary medical institutions in South Korea. Each subject visits the institution according to the protocol that designed the follow-up visits for six months to examine changes in, and factors influencing quality of life (EQ-5D-5L method), patient satisfaction with efficacy and convenience (questionnaire), and safety. This study will approved by the institutions' IRBs and is in compliance with clinical research ethics regulations.
1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.
This study's enrollment of 3,907 is above the median of 174 across 446 observational studies indexed under Osteoporosis.
Browse Osteoporosis studies →Hanmi Pharmaceutical Company Limited is the lead sponsor of 188 studies on the registry; 10 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
Postmenopausal women are at elevated risk of rapid onset osteoporosis, suggesting broad merit in prevention and treatment strategies. This study examines quality of life and patient satisfaction in postmenopausal women receiving raloxifene to prevent/treat osteoporosis, and vitamin D to reduce risk of fracture using clinical practice data.
Exclusion Criteria:
Other Name: Observational Rabone D®, Once daily administered per the locally approved product information
Other: Observational
Rabone D®, Once daily administered per the locally approved product information
The EuroQol EQ-5D
Change and impact factor of quality of life measured with the EuroQol (EQ-5D) EQ-5D-5L is designed to measure health conditions and it consists of 5 questions relating to mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Measuring EQ-5D is performed at each visit. The EQ-5D-5L consists of descriptive system with 5 dimensions. Each dimension has 5 levels: No problems(1), Slight problems(2), Moderate problems(3), Severe problems(4), and Extreme problems(5).
Time frame: 6 months
Medication compliance (Rate of subjects taking more than 80% of the medication)
This study is to learn more about the relationship between quality of life, patient satisfaction and medication compliance. Measuring medication compliance is performed at each visit. The subjects taking more than 80% are defined as compliance group, and the subjects taking less than 80% are defined as non-compliance group. Medication compliance will be compared between compliance group and non-compliance group.
Time frame: 6 months
Treatment satisfaction measured with questionnaire (Patient satisfaction)
This study is to learn more about the relationship between quality of life, patient satisfaction and medication compliance. Measuring patient satisfaction is performed at each visit. Treatment satisfaction is measured with 5 satisfaction degrees(Extremely satisfied, Satisfied, Moderate, Dissatisfied, and Extremely dissatisfied).
Time frame: 6 months
Evaluation of clinical laboratory changes (BTM(Bone turnover marker) CTX)
The following laboratory test is performed at each visit. : CTX (lab unit: e.g. ng/L)
Time frame: 6 months
Evaluation of clinical laboratory changes (BTM(Bone turnover marker) NTX)
The following laboratory test is performed at each visit. : NTX (lab unit: e.g. nM BCE/mM creatinine)
Time frame: 6 months
Evaluation of clinical laboratory changes (BTM(Bone turnover marker) BAP)
The following laboratory test is performed at each visit. : BAP (lab unit: e.g. mcg/L)
Time frame: 6 months
Evaluation of clinical laboratory changes (BTM(Bone turnover marker) P1NP)
The following laboratory test is performed at each visit. : P1NP (lab unit: e.g. μg/L)
Time frame: 6 months
Evaluation of clinical laboratory changes (BTM(Bone turnover marker) osteocalcin)
The following laboratory test is performed at each visit. : osteocalcin (lab unit: e.g. ng/mL)
Time frame: 6 months
Evaluation of clinical laboratory changes (25(OH)D level(25-hydroxyvitamin D level)
The following laboratory test is performed at each visit. : 25(OH)D level(25-hydroxyvitamin D level) (lab unit: e.g. ng/mL)
Time frame: 6 months
Reason for medication change
Reason for medication(prior-medication to prevent/treat osteoporosis and concomitant medications) change is collected at each visit.
Time frame: 6 months
Evaluation of quality of life changes compared with prior medication regimens
This study is to learn more about quality of life changes compared with prior medication regimens. At visit 1, all subjects conduct questionnaire surveys about quality of life. If there are subjects having prior medication regimens for osteoporosis treatment/prevention, these regimens are classified by medication group to compare and evaluate the change in quality of life after taking combination therapy with raloxifene/cholecalciferol. The prior medications are standardized according to ATC(Anatomical Therapeutic Chemical) classification and analyzed based on level 4 and level 5. Change of EQ-5D index according to prior medication regimens is analyzed with average difference of the sum value.
Time frame: 6 months
Occurrence and aspect of adverse events(AEs)
After receiving Rabone D®, new adverse events and detailed information are collected at visit 2 and visit 3.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hanmi Pharmaceutical Company Limited